人游离血红蛋白(F-Hb)说明书
临床检验正常值【范本模板】

临床检验正常值临床检验参考值一。
血液检验(一)血液一般检验血红蛋白(Hbg)男性120—160g/L女性110—150g/L新生儿170-200g/l红细胞(RBC)男性(4。
0-5.5)×1012/L女性(3。
5-5。
0)×1012/L新生儿(6。
0—7。
0) ×1012/L白细胞(WBC)成人(4。
0—10.0)×109/L新生儿(15。
0—20。
0)×109/L6个月至2岁(11。
0-12。
0) ×109/L白细胞分类计数百分率中性杆状核粒细胞0.01—0。
05(1%—5%)中性分叶核粒细胞0.50—0.70(50%-70%)嗜酸性粒细胞0。
005-0.05(0。
5%—5%)嗜碱性粒细胞0—0。
01(0%-1%)淋巴细胞0。
20—0.40(20%—40%)单核细胞0.03-0.08(3%—8%)绝对值中性杆状核粒细胞(0。
04—0。
5) ×109/L中性分叶核粒细胞(2。
0—7.0) ×109/L嗜酸性粒细胞(0。
02-0.5)×109/L嗜碱性粒细胞(0—0.1)×109/L淋巴细胞(0。
8—4。
0)×109/L单核细胞(0.12—0.8) ×109/L点彩红细胞百分率〈0.0001(0。
01%)绝对值〈300/106红细胞嗜多色性红细胞<0。
01(1%)(二)红细胞的其他检验网织红细胞(Rtc) 成人百分数0。
005-0.015(0。
5%-1。
5%) 绝对值(24—84) ×109/L新生儿百分数0.02-0。
06(2%-6%)网织红细胞生成指数(RPI)2红细胞沉降率(ESR) Westergren法男性0—15mm/l小时末女性0-20mm/l 小时末红细胞平均直径6-9µm(平均7。
2µm)红细胞厚度边缘部2µm,中央部1µm血细胞比容(Hct) 微量法男性0.467±0.039L/L女性0。
基于EP-17 A2的胶体金法检测粪便隐血的空白限、检出限及定量限的建立及评价

基于EP-17 A2的胶体金法检测粪便隐血的空白限、检出限及定量限的建立及评价郭绪晓;柏淑美;张春来;袁长金;李金星【期刊名称】《现代检验医学杂志》【年(卷),期】2015(000)001【摘要】目的:参考美国临床实验室标准化委员会(CLSI)发布的《临床实验室检验程序检测能力评价指南(第二版)》(EP-17A2)文件,探讨粪便隐血(FOB)胶体金法检测能力,建立该实验室的空白限(LOB)、检出限(LOD)及定量限(LOQ),减少弱阳性标本漏检率,并为胶体金法的检测限提供定量评价方法。
方法使用人游离血红蛋白(f-Hb)ELISA试剂盒检测新鲜全血制备的系列低浓度的血红蛋白溶液,制定校准曲线,将粪便隐血的空白样本及一系列的血红蛋白低浓度样本使用胶体金试纸条进行检测,利用 Nato Checker710对显色带进行定量检测,并对定量结果进行统计分析,建立胶体金法检测粪便隐血的空白限、检出限及定量限。
结果空白限为99.01 ng/ml,检出限为340.48 ng/ml,定量限为354.9 ng/ml。
结论参考CLSI EP17-A2文件建立的检测限比常规方法建立的检测限科学合理,优于肉眼判断结果,更能满足临床实验室的质量要求和临床早期诊疗的需求;为提高实验室质量管理水平,每批次粪便隐血应根据此方法建立检测限,以及应用于其它项目胶体金法检出限的建立。
【总页数】4页(P78-81)【作者】郭绪晓;柏淑美;张春来;袁长金;李金星【作者单位】山东中医药大学附属医院检验科,济南 250011;山东中医药大学附属医院检验科,济南 250011;山东中医药大学附属医院检验科,济南 250011;山东中医药大学附属医院检验科,济南 250011;山东中医药大学附属医院检验科,济南 250011【正文语种】中文【中图分类】R446.133【相关文献】1.乳胶增强免疫比浊法检测血清降钙素原的空白限、检出限和定量限的建立与评价[J], 陈雪莹2.时间分辨荧光免疫分析法检测乙型肝炎表面抗原空白限,检出限和定量限的建立与评价 [J], 陆亚3.酶联免疫分析检测乙型肝炎e抗原的空白限、检出限及定量限的建立与评价 [J], 胡敏;杨泽华;赵克斌4.化学发光免疫法检测AFP的空白限、检出限和定量检测限的建立与评价 [J], 温冬梅;庞嘉琳;张秀明;王伟佳;黄福达;何娟;肖礼红;欧阳能良;吴剑杨;李曼5.酶联免疫法检测血清乙型肝炎表面抗原的空白限检出限及定量限的建立与评价[J], 谭丽娜;杨泽华;赵克斌因版权原因,仅展示原文概要,查看原文内容请购买。
医学检验·检查项目:血红蛋白浓度(Hb)_课件模板

医学检验·各论:血红蛋白浓度(Hb) >>>
临床意义: 素所致的溶血性贫血以及某些急性或慢性 失血所致的贫血。
医学检验·各论:血红蛋白浓度(Hb) >>>
正常值:
男性 120~160g/L(12.0-16.0g/ dl); 女性 110~150g/L(11.0-15.0g /dl); 新生儿 170~200g/L(18.019.0g/dl)。
医学检验·各论:血红蛋白浓度(Hb) >>>
相关检查: 血清转铁蛋白、红细胞计数(RBC)、蔗糖 溶血试验、血小板计数、骨髓象分析、出 血时间。
医学检验·各论:血红蛋白浓度(Hb) >>>
相关症状: 口腔幻触、劳动耐力下降、眼前发黑、肢 端发绀。
医学检验·各论:血红蛋白浓度(Hb) >>>
相关疾病:
铁利用性贫血、维生素B12缺乏所致贫血、 溶血过度所致贫血、镰状细胞病、地中海 贫血、再生障碍性贫血、肾癌、自身免疫 性溶血性贫血、先天性心脏病、缺铁性贫 血、小儿缺铁性贫血、巨幼细胞性贫血、 大肠癌、结肠癌、胃癌、慢性肺源性心脏 病。
谢谢!
医学检验·各论:血红蛋白浓度(Hb) >>>
临床意义:
血的相对不足,一般可较正常人的低10%20%。妊娠中期和后期由于妊娠血容量增 加而使血液被稀释,老年人由于骨髓造血 功能逐渐降低,可导致红细胞和血红蛋白 含量减少。 (2)病理性减少: A.骨髓造 血功能衰竭,如再生障碍性贫血、骨髓纤 维化所伴发的贫血; B.因造血物质缺乏 或利用障碍所致
医学检验·各论 血红蛋白浓度(Hb)
内容课件模板
医学检验·各论:血红蛋白浓度(Hb) >>>
血浆游离血红蛋白检说明书

血浆游离血红蛋白测定试剂盒说明书(Trinder 法)【产品名称】血浆游离血红蛋白测定试剂盒 【包装规格】R1 100m l ×1 R2 100m l ×1 R3 10m l ×1 血红蛋白标准液 2.00ml ×1 【预期用途】本试剂用于体外在生化分析仪或分光光度计上测定血浆中游离血红蛋白。
【检测原理】血管内溶血时,血浆游离血红蛋白浓度增高。
血红蛋白中亚铁血红素有类似过氧化酶的作用,过氧化氢经过血红蛋白中亚铁血红素催化TBHBA 与4-氨基安替比林生成红色醌亚胺色素,吸收峰为505nm 。
根据显色深度,可测出血浆游离血红蛋白的含量。
【主要组成成份】 R1 TBHBA 稳定剂 R2 4-氨基安替比林 R3 过氧化氢血红蛋白标准液 100 mg/L 【储存条件及有效期】 1. 储存条件 试剂在2-8℃保存 2. 有效期 自生产日期起有效期6个月 【适用仪器】生化分析仪:F-6124;4040; 5010, 分光光度计 【样本要求】血浆 应注意采样及分离血浆过程不得发生溶血 【检验方法 (按表操作) 】 表 操作步骤测定管 标准管 空白管 血浆 (ml) 0.10 - - Hb 标准液 (ml) - 0.10 - 生理盐水 (ml) - - 0.10 R1 (ml) 1.00 1.00 1.00 R2 (ml) 1.00 1.00 1.00 R3 (ml)0.100.100.10混匀,37℃反应20分钟,于生化分析仪或分光光度计上测定,光径10mm ,波长505nm ,空白管调零比色。
计算:标准管吸光度测定管吸光度×100=血浆游离血红蛋白 ( mg/L)【参考值范围】 小于 40 mg/L 【检验结果的解释】血浆游离血红蛋白增加是血管内溶血白的指标,当血管溶血释放的血红蛋白量超过结合珠蛋白所能结合的量时,血浆中游离血红蛋白升高。
多见于较严重的血管内溶血,如阵发性睡眠性血红蛋白尿溶血性输血反应,阵发性寒冷性血红蛋白尿,行军性血红蛋白尿,运动性血红蛋白尿以及各种微血管病性溶血性贫血和一些机械损伤,如体外循环血管内溶血时血浆游离血红蛋白的浓度可达60mg/L ,阵发睡眠性血红蛋白尿可达200-2500mg/L ,血型不合输血可达150-5000mg/L 。
血浆游离血红蛋白测定

血浆游离血红蛋白测定[原理]血红蛋白中亚铁血红素具有类似过氧化物酶的作用,使联苯胺(或邻甲苯胺)氧化,在醋酸溶液中变成绿色、黄色,紫红色。
当血管内溶血时,血浆游离血红蛋白可明显增高。
[试剂](1)联苯胺(或邻甲苯胺)0.1g,加冰醋酸2ml,加蒸馏水3ml,溶解后加95%乙醇至10ml置于4℃冰箱内保存可用1-2周。
(2)取30%H2O2 0.5ml,加蒸馏水14.5ml(新鲜配制)。
(3)10%(v/v)醋酸溶液。
(4)Hb标准液,即用HiCN法精确测得Hb含量,然后配成100mg/L的Hb水溶液.[操作]取大试管(容量为30—50m1)3、支,依次加入下列各液见表(1—3—5)。
表1-3-5 血浆游离血红蛋白测定用波长515nm比色,以空白调零,读取各管吸光度。
[计算]游离血红蛋白(mg/L)=测定管吸光度/标准管吸光度×100。
[参考值]正常人血浆游离血红蛋白<100mg/L(10mg/dl)。
换算系数:mg/L=mg/d1×10编写:孙利制定日期:2011.12.1[临床意义]血管内溶血性贫血、PNH及输不合型的血液后均明显增高,尤其后者可高达5000mg/L以上。
[附注](1)本法系测定细胞溶解,抽血后分离过程应特别注意红细胞破坏而导致结果升高。
(2)显色受温度干扰,要严格遵守测定条件,注意标准管与测定管的比色时间。
(3)由于灵敏度较高,当肉眼见到溶血现象时,标本就应稀释,必要时同时应作1管稀释5倍标本。
(4)因联苯胺具有毒性;测定时可用邻甲苯胶或四甲基联苯胺替代。
(5)纯品联苯胺为无色结晶,纯度不好但可提纯。
联苯胺10g溶于 lmol儿HCl 200ml中,加活性炭1—2g,用力振摇(可稍加热)后过滤,滤液一般无色,否则继续再振摇1—2分钟后,向滤液中加入浓HCl 30ml,混匀置于冰箱过夜即可见大量白色结晶析出,用滤纸过滤后,再用乙醇—乙醚等量混合液洗涤结晶数次,最后用乙醚洗2次即可。
医院检验中心血浆游离血红蛋白测定操作规程

医院检验中心血浆游离血红蛋白测定操作规程[原理]血红蛋白中亚铁血红素具有类似过氧化物酶的作用,使联苯胺(或邻甲苯胺)氧化,在醋酸溶液中变成绿色、黄色,紫红色。
当血管内溶血时,血浆游离血红蛋白可明显增高。
[试剂](1)联苯胺(或邻甲苯胺)0.1g,加冰醋酸2ml,加蒸馏水3ml,溶解后加95%乙醇至10ml置于4℃冰箱内保存可用1-2周。
(2)取30%H2O2 0.5ml,加蒸馏水14.5ml(新鲜配制)。
(3)10%(v/v)醋酸溶液。
(4)Hb标准液,即用HiCN法精确测得Hb含量,然后配成100mg/L的Hb水溶液.[操作]取大试管(容量为30—50m1)3、支,依次加入下列各液见表(1—3—5)。
表1-3-5 血浆游离血红蛋白测定用波长515nm比色,以空白调零,读取各管吸光度。
[计算]游离血红蛋白(mg/L)=测定管吸光度/标准管吸光度×100。
[参考值]正常人血浆游离血红蛋白<100mg/L(10mg/dl)。
换算系数:mg/L=mg/d1×10[临床意义]血管内溶血性贫血、PNH及输不合型的血液后均明显增高,尤其后者可高达5000mg/L以上。
[附注](1)本法系测定细胞溶解,抽血后分离过程应特别注意红细胞破坏而导致结果升高。
(2)显色受温度干扰,要严格遵守测定条件,注意标准管与测定管的比色时间。
(3)由于灵敏度较高,当肉眼见到溶血现象时,标本就应稀释,必要时同时应作1管稀释5倍标本。
(4)因联苯胺具有毒性;测定时可用邻甲苯胶或四甲基联苯胺替代。
(5)纯品联苯胺为无色结晶,纯度不好但可提纯。
联苯胺10g溶于 lmol儿HCl 200ml中,加活性炭1—2g,用力振摇(可稍加热)后过滤,滤液一般无色,否则继续再振摇1—2分钟后,向滤液中加入浓HCl 30ml,混匀置于冰箱过夜即可见大量白色结晶析出,用滤纸过滤后,再用乙醇—乙醚等量混合液洗涤结晶数次,最后用乙醚洗2次即可。
体检项目中的异常指标解析血红蛋白(Hb)水平的意义和解读

体检项目中的异常指标解析血红蛋白(Hb)水平的意义和解读血红蛋白(Hb)是体检中常常被关注的一个指标,对于了解一个人的健康状况至关重要。
本文将从不同角度解析血红蛋白水平的意义和解读,以帮助读者更好地理解和应对体检中的异常指标。
一、什么是血红蛋白(Hb)?血红蛋白是一种存在于红细胞内的蛋白质,其主要作用是运输氧气到身体各个组织和器官中。
它通过与氧气结合形成氧合血红蛋白,从而实现氧气的运输和释放。
血红蛋白的水平直接反映了体内运输氧气的能力和红细胞的数量。
在体检中,测定血红蛋白水平可以帮助医生了解被检者的氧合水平和贫血情况。
二、血红蛋白水平的意义1. 血红蛋白水平反映氧供应能力血红蛋白水平直接关系到身体各个组织和器官的氧供应能力。
如果血红蛋白水平过低,说明氧气供应不足,会导致身体疲乏、无力等不适症状。
反之,如果血红蛋白水平过高,会增加血液的粘稠度,使得氧气难以运输到组织中,进而加重心脑血管负担。
2. 血红蛋白水平对贫血的诊断和监测具有重要意义贫血是指血液中红细胞数量或血红蛋白浓度低于正常范围所致的一种疾病。
通过血红蛋白水平的检测,可以帮助医生判断体内是否存在贫血的情况,并进一步确定贫血的类型和原因。
同时,定期监测血红蛋白水平可以评估贫血的治疗效果,指导治疗方案的制定和调整。
三、血红蛋白水平的解读血红蛋白水平的正常范围会因年龄、性别、生理状态等因素而有所差异。
一般来说,成年男性的正常血红蛋白范围为130-175g/L,而成年女性的正常范围为120-155g/L。
1. 高血红蛋白水平可能的原因高血红蛋白水平可能是由以下几个方面原因导致的:- 高原地区居住或长时间暴露在高海拔环境中;- 长期接触高浓度的一氧化碳或其他有害气体;- 慢性呼吸系统疾病,如慢性阻塞性肺疾病;- 骨髓异常增生或肿瘤等疾病。
2. 低血红蛋白水平可能的原因低血红蛋白水平可能是由以下几个方面原因导致的:- 营养不良,特别是缺铁、维生素B12和叶酸等;- 大量失血,如消化道出血或月经过多;- 骨髓造血功能异常,如再生障碍性贫血;- 慢性疾病,如肾功能不全、乙肝等。
Sigma-Aldrich 08449 血红蛋白说明书

SIGMA-ALDRICH SAFETY DATA SHEETVersion 4.7Revision Date 06/25/2014Print Date 05/17/2016 1. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifiersProduct name : Hemoglobin, from bovine bloodProduct Number : 08449Brand : Sigma-AldrichCAS-No. : 9008-02-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses : Laboratory chemicals, Manufacture of substances1.3 Details of the supplier of the safety data sheetCompany : Sigma-Aldrich3050 Spruce StreetSAINT LOUIS MO 63103USATelephone : +1 800-325-5832Fax : +1 800-325-50521.4 Emergency telephone numberEmergency Phone # : (314) 776-65552. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Hazards not otherwise classified (HNOC) or not covered by GHS -none3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms : Bovine hemoglobinMethemoglobinHbCAS-No. : 9008-02-0No ingredients are hazardous according to OSHA criteria.No components need to be disclosed according to the applicable regulations.4. FIRST AID MEASURES4.1 Description of first aid measuresIf inhaledIf breathed in, move person into fresh air. If not breathing, give artificial respiration.In case of skin contactWash off with soap and plenty of water.In case of eye contactFlush eyes with water as a precaution.If swallowedNever give anything by mouth to an unconscious person. Rinse mouth with water.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 4.3 Indication of any immediate medical attention and special treatment neededno data available5. FIREFIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, alcohol-resistant foam, dry chemical or carbon dioxide.5.2 Special hazards arising from the substance or mixtureNature of decomposition products not known.5.3 Advice for firefightersWear self contained breathing apparatus for fire fighting if necessary.5.4 Further informationno data available6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresAvoid dust formation. Avoid breathing vapours, mist or gas.For personal protection see section 8.6.2 Environmental precautionsDo not let product enter drains.6.3 Methods and materials for containment and cleaning upSweep up and shovel. Keep in suitable, closed containers for disposal.6.4 Reference to other sectionsFor disposal see section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingProvide appropriate exhaust ventilation at places where dust is formed.For precautions see section 2.2.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly closed in a dry and well-ventilated place.Recommended storage temperature: 2 - 8 °CAir and moisture sensitive. Store under inert gas. Keep in a dry place.7.3 Specific end use(s)Apart from the uses mentioned in section 1.2 no other specific uses are stipulated8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersContains no substances with occupational exposure limit values.8.2 Exposure controlsAppropriate engineering controlsGeneral industrial hygiene practice.Personal protective equipmentEye/face protectionUse equipment for eye protection tested and approved under appropriate government standards such asNIOSH (US) or EN 166(EU).Skin protectionHandle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (withouttouching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves afteruse in accordance with applicable laws and good laboratory practices. Wash and dry hands.Full contactMaterial: Nitrile rubberMinimum layer thickness: 0.11 mmBreak through time: 480 minMaterial tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)Splash contactMaterial: Nitrile rubberMinimum layer thickness: 0.11 mmBreak through time: 480 minMaterial tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)datasource:KCLGmbH,D-36124Eichenzell,phone+49(0)665987300,******************,testmethod:EN374If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact thesupplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by anindustrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. Itshould not be construed as offering an approval for any specific use scenario.Body ProtectionChoose body protection in relation to its type, to the concentration and amount of dangerous substances, andto the specific work-place., The type of protective equipment must be selected according to the concentrationand amount of the dangerous substance at the specific workplace.Respiratory protectionRespiratory protection is not required. Where protection from nuisance levels of dusts are desired, use typeN95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved underappropriate government standards such as NIOSH (US) or CEN (EU).Control of environmental exposureDo not let product enter drains.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesa) Appearance Form: powderColour: dark brownb) Odour no data availablec) Odour Threshold no data availabled) pH no data availableno data availablee) Melting point/freezingpointno data availablef) Initial boiling point andboiling rangeg) Flash point no data availableh) Evapouration rate no data availablei) Flammability (solid, gas) no data availableno data availablej) Upper/lowerflammability orexplosive limitsk) Vapour pressure no data availablel) Vapour density no data availablem) Relative density no data availablen) Water solubility no data availableno data available o) Partition coefficient: n-octanol/waterp) Auto-ignitionno data available temperatureno data available q) Decompositiontemperaturer) Viscosity no data availables) Explosive properties no data availablet) Oxidizing properties no data available 9.2 Other safety informationno data available10. STABILITY AND REACTIVITY10.1 Reactivityno data available10.2Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsno data available10.4 Conditions to avoidno data available10.5 Incompatible materialsStrong oxidizing agents10.6 Hazardous decomposition productsOther decomposition products - no data availableIn the event of fire: see section 511. TOXICOLOGICAL INFORMATION11.1Information on toxicological effectsAcute toxicityno data availableInhalation: no data availableDermal: no data availableno data availableSkin corrosion/irritationno data availableSerious eye damage/eye irritationno data availableRespiratory or skin sensitisationno data availableGerm cell mutagenicityno data availableCarcinogenicityIARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.Reproductive toxicityno data availableno data availableSpecific target organ toxicity - single exposureno data availableSpecific target organ toxicity - repeated exposureno data availableAspiration hazardno data availableAdditional InformationRTECS: Not available12. ECOLOGICAL INFORMATION12.1Toxicityno data available12.2Persistence and degradabilityno data available12.3Bioaccumulative potentialno data available12.4 Mobility in soilno data available12.5Results of PBT and vPvB assessmentPBT/vPvB assessment not available as chemical safety assessment not required/not conducted12.6Other adverse effectsno data available13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductOffer surplus and non-recyclable solutions to a licensed disposal company.Contaminated packagingDispose of as unused product.14. TRANSPORT INFORMATIONDOT (US)Not dangerous goodsIMDGNot dangerous goodsIATANot dangerous goods15. REGULATORY INFORMATIONSARA 302 ComponentsSARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 ComponentsSARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 HazardsNo SARA HazardsMassachusetts Right To Know ComponentsNo components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know ComponentsHemoglobins CAS-No.9008-02-0Revision DateNew Jersey Right To Know ComponentsHemoglobins CAS-No.9008-02-0Revision DateCalifornia Prop. 65 ComponentsThis product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.16. OTHER INFORMATIONHMIS RatingHealth hazard: 0Chronic Health Hazard:Flammability: 0Physical Hazard 0NFPA RatingHealth hazard: 0Fire Hazard: 0Reactivity Hazard: 0Further informationCopyright 2014 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to theproduct with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product. See and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.Preparation InformationSigma-Aldrich CorporationProduct Safety – Americas Region1-800-521-8956Version: 4.7Revision Date: 06/25/2014Print Date: 05/17/2016。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
人游离血红蛋白(F-Hb)酶联免疫分析(ELISA)试剂盒使用说明书本试剂仅供研究使用目的:本试剂盒用于测定人全血样本中游离血红蛋白(F-Hb)的含量。
实验原理:本试剂盒应用双抗体夹心法测定标本中人游离血红蛋白(F-Hb)水平。
用纯化的人游离血红蛋白(F-Hb)抗体包被微孔板,制成固相抗体,往包被单抗的微孔中依次加入游离血红蛋白(F-Hb),再与HRP标记的游离血红蛋白(F-Hb)抗体结合,形成抗体-抗原-酶标抗体复合物,经过彻底洗涤后加底物TMB显色。
TMB在HRP酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。
颜色的深浅和样品中的游离血红蛋白(F-Hb)呈正相关。
用酶标仪在450nm波长下测定吸光度(OD值),通过标准曲线计算样品中人游离血红蛋白(F-Hb)浓度。
试剂盒组成:试剂盒组成48孔配置96孔配置保存说明书1份1份封板膜2片(48)2片(96)密封袋1个1个酶标包被板1×481×962-8℃保存标准品:540μg/ml0.5ml×1瓶0.5ml×1瓶2-8℃保存标准品稀释液 1.5ml×1瓶 1.5ml×1瓶2-8℃保存酶标试剂3ml×1瓶6ml×1瓶2-8℃保存样品稀释液3ml×1瓶6ml×1瓶2-8℃保存显色剂A液3ml×1瓶6ml×1瓶2-8℃保存显色剂B液3ml×1瓶6ml×1瓶2-8℃保存终止液3ml×1瓶6ml×1瓶2-8℃保存浓缩洗涤液(20ml×20倍)×1瓶(20ml×30倍)×1瓶2-8℃保存样本处理及要求:1.血清:室温血液自然凝固10-20分钟,离心20分钟左右(2000-3000转/分)。
仔细收集上清,保存过程中如出现沉淀,应再次离心。
2.血浆:应根据标本的要求选择EDTA或柠檬酸钠作为抗凝剂,混合10-20分钟后,离心20分钟左右(2000-3000转/分)。
仔细收集上清,保存过程中如有沉淀形成,应该再次离心。
3.尿液:用无菌管收集,离心20分钟左右(2000-3000转/分)。
仔细收集上清,保存过程中如有沉淀形成,应再次离心。
胸腹水、脑脊液参照实行。
4.细胞培养上清:检测分泌性的成份时,用无菌管收集。
离心20分钟左右(2000-3000转/分)。
仔细收集上清。
检测细胞内的成份时,用PBS(PH7.2-7.4)稀释细胞悬液,细胞浓度达到100万/ml左右。
通过反复冻融,以使细胞破坏并放出细胞内成份。
离心20分钟左右(2000-3000转/分)。
仔细收集上清。
保存过程中如有沉淀形成,应再次离心。
5.组织标本:切割标本后,称取重量。
加入一定量的PBS,PH7.4。
用液氮迅速冷冻保存备用。
标本融化后仍然保持2-8℃的温度。
加入一定量的PBS(PH7.4),用手工或匀浆器将标本匀浆充分。
离心20分钟左右(2000-3000转/分)。
仔细收集上清。
分装后一份待检测,其余冷冻备用。
6.标本采集后尽早进行提取,提取按相关文献进行,提取后应尽快进行实验。
若不能马上进行试验,可将标本放于-20℃保存,但应避免反复冻融.7.不能检测含NaN3的样品,因NaN3抑制辣根过氧化物酶的(HRP)活性。
操作步骤1.标准品的稀释与加样:在酶标包被板上设标准品孔10孔,在第一、第二孔中分别加标准品100μl,然后在第一、第二孔中加标准品稀释液50μl,混匀;然后从第一孔、第二孔中各取100μl分别加到第三孔和第四孔,再在第三、第四孔分别加标准品稀释液50μl,混匀;然后在第三孔和第四孔中先各取50μl弃掉,再各取50μl分别加到第五、第六孔中,再在第五、第六孔中分别加标准品稀释液50ul,混匀;混匀后从第五、第六孔中各取50μl分别加到第七、第八孔中,再在第七、第八孔中分别加标准品稀释液50μl,混匀后从第七、第八孔中分别取50μl加到第九、第十孔中,再在第九第十孔分别加标准品稀释液50μl,混匀后从第九第十孔中各取50μl弃掉。
(稀释后各孔加样量都为50μl,浓度分别为360μg/ml,240μg/ml,120μg/ml,60μg/ml,30μg/ml)。
2.加样:分别设空白孔(空白对照孔不加样品及酶标试剂,其余各步操作相同)、待测样品孔。
在酶标包被板上待测样品孔中先加样品稀释液40μl,然后再加待测样品10μl(样品最终稀释度为5倍)。
加样将样品加于酶标板孔底部,尽量不触及孔壁,轻轻晃动混匀。
3.温育:用封板膜封板后置37℃温育30分钟。
4.配液:将30(48T的20倍)倍浓缩洗涤液用蒸馏水30(48T的20倍)倍稀释后备用。
5.洗涤:小心揭掉封板膜,弃去液体,甩干,每孔加满洗涤液,静置30秒后弃去,如此重复5次,拍干。
6.加酶:每孔加入酶标试剂50μl,空白孔除外。
7.温育:操作同3。
8.洗涤:操作同5。
9.显色:每孔先加入显色剂A50μl,再加入显色剂B50μl,轻轻震荡混匀,37℃避光显色15分钟.10.终止:每孔加终止液50μl,终止反应(此时蓝色立转黄色)。
11.测定:以空白空调零,450nm波长依序测量各孔的吸光度(OD值)。
测定应在加终止液后15分钟以内进行。
注意事项:1.试剂盒从冷藏环境中取出应在室温平衡15-30分钟后方可使用,酶标包被板开封后如未用完,板条应装入密封袋中保存。
2.浓洗涤液可能会有结晶析出,稀释时可在水浴中加温助溶,洗涤时不影响结果。
3.各步加样均应使用加样器,并经常校对其准确性,以避免试验误差。
一次加样时间最好控制在5分钟内,如标本数量多,推荐使用排枪加样。
4.请每次测定的同时做标准曲线,最好做复孔。
如标本中待测物质含量过高(样本OD值大于标准品孔第一孔的OD值),请先用样品稀释液稀释一定倍数(n倍)后再测定,计算时请最后乘以总稀释倍数(×n×5)。
5.封板膜只限一次性使用,以避免交叉污染。
6.底物请避光保存。
7.严格按照说明书的操作进行,试验结果判定必须以酶标仪读数为准.8.所有样品,洗涤液和各种废弃物都应按传染物处理。
9.本试剂不同批号组分不得混用。
10.如与英文说明书有异,以英文说明书为准。
计算:以标准物的浓度为横坐标,OD值为纵坐标,在坐标纸上绘出标准曲线,根据样品的OD值由标准曲线查出相应的浓度;再乘以稀释倍数;或用标准物的浓度与OD值计算出标准曲线的直线回归方程式,将样品的OD值代入方程式,计算出样品浓度,再乘以稀释倍数,即为样品的实际浓度。
(此图仅供参考)试剂盒性能:1.样品线性回归与预期浓度相关系数R值为0.990以上。
2.批内与批间应分别小于9%和11%检测范围:20μg/ml-400μg/ml保存条件及有效期:1.试剂盒保存:;2-8℃。
2.有效期:6个月Human F-HbFOR RESEARCH USE ONLYDrug NamesGeneric Name:Human F-Hb ELISA Kit.PurposeThis kit allows for the determination of F-Hb concentrations in Human whole blood. Principle of the assayT he kit assay Human F-Hb level in the sample,use Purified Human F-Hb antibody to coat microtiter plate wells,make solid-phase antibody,then add F-Hb to wells,Combined F-Hb antibody which With HRP labeled,become antibody-antigen-enzyme-antibody complex, after washing Completely,Add TMB substrate solution,TMB substrate becomes blue color At HRP enzyme-catalyzed,reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of450nm.The concentration of F-Hb in the samples is then determined by comparing the O.D.of the samples to the standard curve.Materials provided with the kitMaterials provided withthe kit48determinations96determinations Storage User manual11Closure plate membrane22Sealed bags11Microelisa stripplate112-8℃Standard:540μg/ml0.5ml×1bottle0.5ml×1bottle2-8℃Standard diluent 1.5ml×1bottle 1.5ml×1bottle2-8℃HRP-Conjugate reagent3ml×1bottle6ml×1bottle2-8℃Sample diluent3ml×1bottle6ml×1bottle2-8℃Chromogen Solution A3ml×1bottle6ml×1bottle2-8℃Chromogen Solution B3ml×1bottle6ml×1bottle2-8℃Stop Solution3ml×1bottle6ml×1bottle2-8℃wash solution(20ml×20fold)×1bottle (20ml×30fold)×1bottle2-8℃Specimen requirements1.serum-coagulation at room temperature10-20mins,centrifugation20-min at the speed of2000-3000r.p.m.remove supernatant,If precipitation appeared,Centrifugal again.2.plasma-use suited EDTA or citrate plasma as an anticoagulant,mix10-20mins,centrifugation20-min at the speed of2000-3000r.p.m.remove supernatant,If precipitation appeared,Centrifugal again.3.Urine-collect sue a sterile container,centrifugation20-min at the speed of2000-3000r.p.m.remove supernatant,If precipitation appeared,Centrifugal again.The Operation of Hydrothorax and cerebrospinal fluid Reference to it.4.cell culture supernatant-detect secretory components,collect sue a sterile container,centrifugation20-min at the speed of2000-3000r.p.m.remove supernatant,detect the composition of cells,Dilut cell suspension with PBS(PH7.2-7.4),Cell concentration reached1million/ml,repeated freeze-thaw cycles,damage cells and release of intracellular components,centrifugation20-min at the speed of2000-3000r.p.m.remove supernatant,If precipitation appeared,Centrifugal again.5.Tissue samples-After cutting samples,check the weight,add PBS(PH7.2-7.4),Rapidlyfrozen with liquid nitrogen,maintain samples at2-8℃after melting,add PBS(PH7.4),Homogenized by hand or Grinders,centrifugation20-min at the speed of2000-3000r.p.m.remove supernatant.6.extract as soon as possible after Specimen collection,and according to the relevantliterature,and should be experiment as soon as possible after the extraction.If it can’t, specimen can be kept in-20℃to preserve,Avoid repeated freeze-thaw cycles.7.Can’t detect the sample which contain NaN3,because NaN3inhibits HRP active. Assay procedure1.Dilute and add sample to Standard:set10Standard wells on the ELISA plates coated,add Standard100μl to the first and the second well,then add Standard dilution50μl to the first and the second well,mix;take out100μl form the first and the second well then add it to the third and the forth well separately.then add Standard dilution50μl to the third and the forth well,mix;then take out50μl from the third and the forth well discard,add50μl to the fifth and the sixth well,then add Standard dilution50μl to the fifth and the sixth well,mix;take out50μl from the fifth and the sixth well and add to the seventh and the eighth well,then add Standard dilution50μl to the seventh and the eighth well,mix;take out50μl from the seventh and the eighth well and add to the ninth and the tenth well,add Standard dilution50μl to the ninth and the tenth well,mix,take out50μl from the ninth and the tenth well discard(add Sample50μl to each well after Diluting,(density:360μg/ml,240μg/ml,120μg/ml,60μg/ml,30μg/ml)2.add sample:Set blank wells separately(blank comparison wells don’t add sample and HRP-Conjugate reagent,other each step operation is same).testing sample well.add Sample dilution40μl to testing sample well,then add testing sample10μl(sample final dilution is 5-fold),add sample to wells,don’t touch the well wall as far as possible,and Gently mix.3.Incubate:After closing plate with Closure plate membrane,incubate for30min at37℃.4.Configurate liquid:30-fold(or20-fold)wash solution diluted30-fold(or20-fold)with distilled water and reserve.5.washing:Uncover Closure plate membrane,discard Liquid,dry by swing,add washing buffer to every well,still for30s then drain,repeat5times,dry by pat.6.add enzyme:Add HRP-Conjugate reagent50μl to each well,except blank well.7.incubate:Operation with3.8.washing:Operation with5.9.color:Add Chromogen Solution A50ul and Chromogen Solution B to each well,evade the light preservation for15min at37℃10.Stop the reaction:Add Stop Solution50μl to each well,Stop the reaction(the blue color change to yellow color).11.assay:take blank well as zero,Read absorbance at450nm after Adding Stop Solution and within15min.Important notes1.The kit takes out from the refrigeration environment should be balanced15-30minutes inthe room temperature,ELISA plates coated if has not use up after opened,the plate should be stored in Sealed bag.2.washing buffer will Crystallization separation,it can be heated the water helps dissolvewhen dilute.Washing does not affect the result.3.add Sample with sampler Each step,And proofread its accuracy frequently,avoids theexperimental error.add sample within5mins,if the number of sample is much, recommend to use Volley.4.if the testing material content is excessively higher(The sample OD is bigger than the firststandard well),please dilute Sample(n-fold),Please diluente and multiplied by the dilution factor.(×n×5).5.Closure plate membrane only limits the disposable use,to avoid cross-contamination.6.The substrate evade the light preservation.7.Please according to use instruction strictly,The test result determination must take themicrotiter plate reader as a standard.8.All samples,washing buffer and each kind of reject should according to infective materialprocess.9.Do not mix reagents with those from other lots.CalculateAssayrange20μg/ml -400μg/mlStorage and validity1.Storage :2-8℃.2.validity :six months.Take the standard density as the horizontal,the OD value for the vertical ,draw the standard curve on graph paper,Find out the corresponding density according to the sample OD value by the Sample curve,multiplied by the dilution multiple,or calculate the straight line regression equation of the standard curve with the standard density and the OD value ,with the sample OD value in the equation,calculate the sample density,multiplied by the dilution factor,the result is the sample actual density.This chartis for reference only。